Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy? by Wiebren Tjalma, Laure-Anne Teuwen, Sevilay Altintas, Konstantinos Papadimitriou

Get full text

LymphSens study: the enigma of subjective lymphoedema – how often and why do patients report lymphoedema after breast cancer treatment without an objective measurable swelling? The... by An De Groef, Nele Devoogdt, Ann Smeets, Mira Meeus, Vaughan Keeley, Sarah Thomis, Steffen Fieuws, Karin Johansson, Nieke Vets, Kaat Verbeelen, Ceren Gursen, Laura Spincemaille, Hans Vanderheyden, Nick Gebruers, Wiebren Tjalma

Get full text

Study protocol for a pragmatic randomised controlled trial in Belgian primary care and hospital settings on the effectiveness of an eHealth self-management support programme consis... by Josefien van Olmen, An De Groef, Nele Devoogdt, Lore Dams, Bart Morlion, Mira Meeus, G Lorimer Moseley, Louise K Wiles, Peter Hibbert, Patrick Neven, Ines Nevelsteen, Steffen Fieuws, Geert Crombez, Michel Mertens, Ceren Gursen, Wiebren Tjalma, Lander Willem, Lauren C Heathcote, Mark Catley, Anna Vogelzang, Marthe Van Overbeke, Emma Tack, Sophie Van Dijck, Annick L De Paepe, Rani Vanhoudt, Davina Wildemeersch, Femke De Backere

Get full text